RT Journal Article
SR Electronic
T1 Chromatin remodeler <em>developmental pluripotency associated factor 4</em> (<em>DPPA4</em>) is a candidate gene for alcohol-induced developmental disorders
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.14.22273502
DO 10.1101/2022.04.14.22273502
A1 Auvinen, P
A1 Vehviläinen, J
A1 Marjonen, H
A1 Modhukur, V
A1 Sokka, J
A1 Wallén, E
A1 Rämö, K
A1 Ahola, L
A1 Salumets, A
A1 Otonkoski, T
A1 Skottman, H
A1 Ollikainen, M
A1 Trokovic, R
A1 Kahila, H
A1 Kaminen-Ahola, N
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.14.22273502.abstract
AB Alcohol affects embryonic development, causing a variable fetal alcohol spectrum disorder (FASD) phenotype with neuronal disorders and birth defects. To explore the etiology of FASD, we collected an exceptional cohort of 80 severely alcohol-exposed and 100 control newborns and performed genome-wide DNA methylation and gene expression analyses of placentas. DPPA4, FOXP2, and TACR3 with significantly decreased DNA methylation were discovered – particularly the regulatory region of DPPA4 in the early alcohol-exposed placentas. When human embryonic stem cells (hESCs) were exposed to alcohol in vitro, significantly altered regulation of DPPA2, a closely linked heterodimer of DPPA4, was observed. While the regulatory region of DPPA4 was unmethylated in both control and alcohol-exposed hESCs, alcohol-induced decreased DNA methylation similar to placenta was seen in in vitro differentiated mesodermal and ectodermal cells. Furthermore, common genes with alcohol-associated DNA methylation changes in placenta and hESCs were linked exclusively to the neurodevelopmental pathways, which emphasizes the value of placental tissue when analyzing the effects of prenatal environment on human development. Our study shows the effects of early alcohol exposure on human embryonic and extraembryonic cells, introduces candidate genes for alcohol-induced developmental disorders, and reveals potential biomarkers for prenatal alcohol exposure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the Academy of Finland (332212), University of Helsinki (Early Career Investigator Funding, Faculty of Medicine), Finnish Foundation for Alcohol Studies, Yrjo Jahnsson Foundation, Juha Vainio Foundation, and Paulo Foundation (N.K-A.), Finnish Cultural Foundation (00190186, 00200185, and 00212573) (P.A.), Finnish Foundation for Alcohol Studies (H.M.), Estonian Research Council (PRG1076), Horizon 2020 innovation (ERIN, EU952516) and European Commission and Enterprise Estonia (EU48695) (A.S.), Jane and Aatos Erkko Foundation, Academy of Finland (297466, 312437), and Center of Excellence in Stem Cell Metabolism (T.O.), Academy of Finland (297886) (H.S.), Academy of Finland (297908 and 328685) and Sigrid Juselius Foundation) (M.O.), as well as Sigrid Juselius Foundation (R.T.)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from all participants and the study was approved by the Ethics Committee of Helsinki University Central Hospital (386/13/03/03/2012). hESC cell line H1 (WA01) was obtained from Biomedicum Stem Cell Center (BSCC, Helsinki, Finland) through a license agreement with WiCell, Inc. and Regea08/017 from Skottman laboratory (Tampere, Finland) approved by the Ethics Committee of Tampere University Hospital (Skottman/R05116).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets supporting the conclusions of the current study are included within the article and its additional files. Due to the sensitive nature of the patient data used, the data sets are not and cannot be made publicly available. All data produced in the present study are available upon reasonable request to the authors.The datasets supporting the conclusions of the current study are included within the article and its additional files. Due to the sensitive nature of the patient data used, the data sets are not and cannot be made publicly available. All data produced in the present study are available upon reasonable request to the authors.